David F Stroncek

List of Publications by Year in descending order

264 papers	12,748 citations	38720 50 h-index	29127 104 g-index
275 all docs	275 docs citations	275 times ranked	15159 citing authors

#	Article	IF	Citations
1	Transfusion-related acute lung injury: Definition and review. Critical Care Medicine, 2005, 33, 721-726.	0.4	1,147
2	CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nature Medicine, 2018, 24, 20-28.	15.2	1,030
3	T cells expressing an antiâ€“B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood, 2016, 128, 1688-1700.	0.6	626
4	T Cells Genetically Modified to Express an Antiâ€“B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. Journal of Clinical Oncology, 2018, 36, 2267-2280.	0.8	570
5	NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature, 2016, 531, 253-257.	13.7	552
6	The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study. Transfusion, 1997, 37, 719-726.	0.8	403
7	International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy, 2016, 18, 151-159.	0.3	400
8	Platelet transfusions. Lancet, The, 2007, 370, 427-438.	6.3	276
9	Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood, 2016, 128, 519-528.	0.6	274
10	CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. Journal of Clinical Oncology, 2020, 38, 1938-1950.	0.8	273
11	Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cellâ€“depleted stem cell transplantation. Blood, 2015, 125, 784-792.	0.6	200
12	Gene expression profiling of cutaneous wound healing. Journal of Translational Medicine, 2007, 5, 11.	1.8	183
13	Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nature Medicine, 2020, 26, 270-280.	15.2	182
14	Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. Journal of Clinical Oncology, 2021, 39, 1650-1659.	0.8	173
15	MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. Journal of Translational Medicine, 2009, 7, 20.	1.8	165
16	TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nature Medicine, 2021, 27, 419-425.	15.2	156
17	Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight, 2017, 2, .	2.3	142
18	Transfusion-related acute lung injury caused by an NB2 granulocyte- specific antibody in a patient with thrombotic thrombocytopenic purpura. Transfusion, 1990, 30, 42-45.	0.8	139

#	Article	IF	Citations
19	Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood, 2013, 121, 197-206.	0.6	123
20	Human mesenchymal stromal cell-secreted lactate induces M2-macrophage differentiation by metabolic reprogramming. Oncotarget, 2016, 7, 30193-30210.	0.8	116
21	Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment. Journal of Immunotherapy, 2012, 35, 283-292.	1.2	114
22	Autologous lymphapheresis for the production of chimeric antigen receptor TÂcells. Transfusion, 2017, 57, 1133-1141.	0.8	110
23	Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. Journal of Translational Medicine, 2010, 8, 4.	1.8	109
24	Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells. Cytotherapy, 2016, 18, 893-901.	0.3	104
25	Monocyte-derived DC maturation strategies and related pathways: a transcriptional view. Cancer Immunology, Immunotherapy, 2011, 60, 457-466.	2.0	102
26	Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 218-218.	0.6	98
27	Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures. Blood, 2009, 114, 2530-2541.	0.6	95
28	G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion, 2003, 43, 609-613.	0.8	94
29	Simplified process for the production of antiâ€“CD19-CARâ€“engineered TÂcells. Cytotherapy, 2013, 15, 1406-1415.	0.3	91
30	Superparamagnetic Iron Oxide Nanoparticles Labeling of Bone Marrow Stromal (Mesenchymal) Cells Does Not Affect Their â€œStemnessâ€• PLoS ONE, 2010, 5, e11462.	1.1	89
31	Molecular basis of the neutrophil glycoprotein NB1 (CD177) involved in the pathogenesis of immune neutropenias and transfusion reactions. European Journal of Immunology, 2001, 31, 1301-1309.	1.6	86
32	Bone Marrow Mesenchymal Stromal Cells to Treat Tissue Damage in Allogeneic Stem Cell Transplant Recipients: Correlation of Biological Markers with Clinical Responses. Stem Cells, 2014, 32, 1278-1288.	1.4	83
33	Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood, 2021, 138, 2469-2484.	0.6	79
34	Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis. Journal of Translational Medicine, 2008, 6, 39.	1.8	77
35	Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics, 2009, 10, 301.	1.2	77
36	Administration of G-CSF plus dexamethasone producesgreater granulocyte concentrate yields while causing nomore donor toxicity than G-CSF alone. Transfusion, 2001, 41, 1037-1044.	0.8	75

#	Article	IF	Citations
37	HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. Blood, 2006, 107, 1680-1687.	0.6	71
38	Interferon-Î³ and Tumor Necrosis Factor-Î± Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype. Scientific Reports, 2016, 6, 26345.	1.6	69
39	CD177: A member of the Ly-6 gene superfamily involved with neutrophil proliferation and polycythemia vera. Journal of Translational Medicine, 2004, 2, 8.	1.8	67
40	Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics. Molecular Therapy, 2019, 27, 1275-1285.	3.7	65
41	Neutrophil-specific antigen HNA-2a, NB1 glycoprotein, and CD177. Current Opinion in Hematology, 2007, 14, 688-693.	1.2	64
42	Manufacturing Differences Affect Human Bone Marrow Stromal Cell Characteristics and Function: Comparison of Production Methods and Products from Multiple Centers. Scientific Reports, 2017, 7, 46731.	1.6	64
43	Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States. Blood, 2010, 115, 5097-5101.	0.6	63
44	Comparison of proteomic profiles of serum, plasma, and modified media supplements used for cell culture and expansion. Journal of Translational Medicine, 2006, 4, 40.	1.8	62
45	Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells. Journal of Translational Medicine, 2017, 15, 59.	1.8	61
46	Therapeutic apheresis for babesiosis. , 1998, 13, 32-36.		59
47	Global transcriptome analysis of human bone marrow stromal cells (BMSC) reveals proliferative, mobile and interactive cells that produce abundant extracellular matrix proteins, some of which may affect BMSC potency. Cytotherapy, 2011, 13, 661-674.	0.3	59
48	Tbet and IL-36Î³ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment. OncoImmunology, 2017, 6, e1322238.	2.1	59
49	Effects of Storage Time and Exogenous Protease Inhibitors on Plasma Protein Levels. American Journal of Clinical Pathology, 2006, 126, 174-184.	0.4	57
50	Intra-subject variability in human bone marrow stromal cell (BMSC) replicative senescence: Molecular changes associated with BMSC senescence. Stem Cell Research, 2013, 11, 1060-1073.	0.3	57
51	Sources of Hematopoietic Stem and Progenitor Cells and Methods to Optimize Yields for Clinical Cell Therapy. Biology of Blood and Marrow Transplantation, 2017, 23, 1241-1249.	2.0	55
52	Selectively T Cell-Depleted Allografts from HLA-Matched Sibling Donors Followed by Low-Dose Posttransplantation Immunosuppression to Improve Transplantation Outcome in Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2011, 17, 1855-1861.	2.0	52
53	Comparison of endometrial regenerative cells and bone marrow stromal cells. Journal of Translational Medicine, 2012, 10, 207.	1.8	50
54	Leukemia cells induce changes in human bone marrow stromal cells. Journal of Translational Medicine, 2013, 11, 298.	1.8	50

#	Article	IF	Citations
55	Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease. Journal of Immunology, 2016, 197, 3490-3503.	0.4	50
56	The transfusion of neutrophil-specific antibodies causes leukopenia and a broad spectrum of pulmonary reactions. Transfusion, 2007, 47, 545-550.	0.8	47
57	Evaluation of the gel system for ABO grouping and D typing. Transfusion, 1999, 39, 300-305.	0.8	46
58	Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a. Journal of Translational Medicine, 2009, 7, 39.	1.8	46
59	Generation of clinical grade human bone marrow stromal cells for use in bone regeneration. Bone, 2015, 70, 87-92.	1.4	46
60	A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". Journal of Translational Medicine, 2008, 6, 81.	1.8	45
61	15 kDa Granulysin Causes Differentiation of Monocytes to Dendritic Cells but Lacks Cytotoxic Activity. Journal of Immunology, 2012, 188, 6119-6126.	0.4	45
62	Granulocyte transfusions in the management of invasive fungal infections. British Journal of Haematology, 2017, 177, 357-374.	1.2	44
63	Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. Journal of Translational Medicine, 2006, 4, 26.	1.8	42
64	The establishment of a bank of stored clinical bone marrow stromal cell products. Journal of Translational Medicine, 2012, 10, 23.	1.8	42
65	Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse. Biology of Blood and Marrow Transplantation, 2016, 22, 2149-2154.	2.0	42
66	Neutrophil alloantigens. Transfusion Medicine Reviews, 2002, 16, 67-75.	0.9	41
67	Systemic translocation of Staphylococcus drives autoantibody production in HIV disease. Microbiome, 2019, 7, 25.	4.9	39
68	Cancer vaccine strategies: translation from mice to human clinical trials. Cancer Immunology, Immunotherapy, 2018, 67, 1863-1869.	2.0	38
69	CD177 polymorphisms: correlation between high-frequency single nucleotide polymorphisms and neutrophil surface protein expression. Transfusion, 2004, 44, 77-82.	0.8	36
70	Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System. Cell Reports, 2018, 22, 3175-3190.	2.9	35
71	Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules. Journal of Translational Medicine, 2018, 16, 13.	1.8	35
72	Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia. Blood, 2015, 126, 684-684.	0.6	35

#	Article	IF	Citations
73	Sickle Hb polymerization in RBC components from donors with sickle cell trait prevents effective WBC reduction by filtration. Transfusion, 2002, 42, 1466-1472.	0.8	34
74	The subcellular distribution of myeloid-related protein 8 (MRP8) and MRP14 in human neutrophils. Journal of Translational Medicine, 2005, 3, 36.	1.8	34
75	Potency analysis of cellular therapies: the emerging role of molecular assays. Journal of Translational Medicine, 2007, 5, 24.	1.8	34
76	Human bone marrow stromal cell confluence: effects on cell characteristics and methods of assessment. Cytotherapy, 2015, 17, 897-911.	0.3	34
77	Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). Blood, 2016, 128, 650-650.	0.6	34
78	Expression of human neutrophil antigen-2a (NB1) is increased in pregnancy. Transfusion, 2003, 43, 357-363.	0.8	33
79	Kinetics of G-CSF-induced granulocyte mobilization in healthy subjects: effects of route of administration and addition of dexamethasone. Transfusion, 2002, 42, 597-602.	0.8	32
80	The gene overexpressed in polycythemia rubra vera, PRV-1, and the gene encoding a neutrophil alloantigen, NB1, are alleles of a single gene, CD177, in chromosome band 19q13.31. Transfusion, 2006, 46, 441-447.	0.8	32
81	Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies. Journal of Translational Medicine, 2014, 12, 241.	1.8	32
82	Comparison of DATs using traditional tube agglutination to gel column and affinity column procedures. Transfusion, 2001, 41, 1258-1262.	0.8	31
83	Identification of Immune Dominant Cytomegalovirus Epitopes Using Quantitative Real-Time Polymerase Chain Reactions to Measure Interferon-Î³ Production by Peptide-Stimulated Peripheral Blood Mononuclear Cells. Journal of Immunotherapy, 2002, 25, 342-351.	1.2	31
84	Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood, 2013, 121, 2864-2874.	0.6	31
85	Quantitative activation suppression assay to evaluate human bone marrowâ€“derived mesenchymal stromal cell potency. Cytotherapy, 2015, 17, 1675-1686.	0.3	31
86	Neutrophil-Specific Antigen NB1 Is Anchored Via a Glycosyl-Phosphatidylinositol Linkage. Journal of Leukocyte Biology, 1991, 49, 163-171.	1.5	30
87	Changes in serum osteocalcin and bone-specific alkaline phosphatase are associated with bone pain in donors receiving granulocyte-colony-stimulating factor for peripheral blood stem and progenitor cell collection. Transfusion, 1999, 39, 410-414.	0.8	30
88	Leukocyte Antigen and Antibody Detection Assays: Tools for Assessing and Preventing Pulmonary Transfusion Reactions. Transfusion Medicine Reviews, 2007, 21, 273-286.	0.9	30
89	Developments in clinical cell therapy. Cytotherapy, 2010, 12, 425-428.	0.3	29
90	The stable traits of melanoma genetics: an alternate approach to target discovery. BMC Genomics, 2012, 13, 156.	1.2	29

#	Article	IF	Citations
91	Comparative analyses of industrialâ€scale human platelet lysate preparations. Transfusion, 2017, 57, 2858-2869.	0.8	29
92	Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor. Haematologica, 2020, 105, e497.	1.7	29
93	The Use of Bioinformatics to Identify the Genomic Structure of the Gene That Encodes Neutrophil Antigen NB1, CD177. Clinical Immunology, 2002, 102, 138-144.	1.4	28
94	Analysis of the recovery of cryopreserved and thawed <scp>CD</scp>34+ and <scp>CD</scp>3+ cells collected for hematopoietic transplantation. Transfusion, 2014, 54, 1088-1092.	0.8	28
95	The immuneâ€related role of BRAF in melanoma. Molecular Oncology, 2015, 9, 93-104.	2.1	28
96	Human Mesenchymal Stromal Cell (MSC) Characteristics Vary Among Laboratories When Manufactured From the Same Source Material: A Report by the Cellular Therapy Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Frontiers in Cell and Developmental Biology, 2020, 8, 458.	1.8	28
97	Granulocyte transfusions in children and adults with hematological malignancies: benefits and controversies. Journal of Translational Medicine, 2015, 13, 362.	1.8	26
98	Effects of starting cellular material composition on chimeric antigen receptor Tâ€cell expansion and characteristics. Transfusion, 2019, 59, 1755-1764.	0.8	26
99	Storage of G-CSF-mobilized granulocyte concentrates. Transfusion, 2000, 40, 1104-1110.	0.8	25
100	Single cell sequencing reveals gene expression signatures associated with bone marrow stromal cell subpopulations and time in culture. Journal of Translational Medicine, 2019, 17, 23.	1.8	25
101	Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms. Journal of Translational Medicine, 2005, 3, 24.	1.8	24
102	Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest. Cancer Immunology Research, 2015, 3, 37-47.	1.6	24
103	TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. OncoImmunology, 2016, 5, e1197459.	2.1	24
104	Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients. Clinical Cancer Research, 2017, 23, 3352-3364.	3.2	24
105	Comparison of human bone marrow stromal cells cultured in human platelet growth factors and fetal bovine serum. Journal of Translational Medicine, 2018, 16, 65.	1.8	24
106	Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease. Blood Advances, 2021, 5, 2403-2411.	2.5	24
107	BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study. Lancet Neurology, The, 2021, 20, 639-652.	4.9	24
108	T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial. Blood, 2016, 128, 999-999.	0.6	24

#	Article	IF	Citations
109	Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates. Transfusion, 2016, 56, 511-517.	0.8	23
110	High Throughput Hla Sequence-Based Typing (Sbt) Utilizing the Abi PrismÂ® 3700 Dna Analyzer. Tumori, 2001, 87, 40-43.	0.6	22
111	Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF. Journal of Translational Medicine, 2004, 2, 25.	1.8	22
112	Improving CAR T cell therapy by optimizing critical quality attributes. Seminars in Hematology, 2020, 57, 33-38.	1.8	22
113	Regression of epithelial cancers in humans following t-cell receptor gene therapy targeting human papillomavirus-16 E7.. Journal of Clinical Oncology, 2018, 36, 3043-3043.	0.8	22
114	Biotinylation modifies red cell antigens. Transfusion, 1999, 39, 163-168.	0.8	21
115	Recent advances in the bcr-abl negative chronic myeloproliferative diseases. Journal of Translational Medicine, 2006, 4, 41.	1.8	21
116	Establishing a Bone Marrow Stromal Cell Transplant Program at the National Institutes of Health Clinical Center. Tissue Engineering - Part B: Reviews, 2014, 20, 200-205.	2.5	21
117	Immunotherapy biomarkers 2016: overcoming the barriers. , 2017, 5, 29.		21
118	Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 1324-1324.	0.6	21
119	Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. , 2022, 10, e004483.		21
120	Drug-induced hemolysis: Cefotetan-dependent hemolytic anemia mimicking an acute intravascular immune transfusion reaction. , 2000, 64, 67-70.		20
121	Long-Term Outcome of Fludarabine-Based Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Debilitating Paroxysmal Nocturnal Hemoglobinuria. Biology of Blood and Marrow Transplantation, 2014, 20, 1435-1439.	2.0	20
122	Systematic evaluation of immune regulation and modulation. , 2017, 5, 21.		20
123	Remissions of Multiple Myeloma during a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor. Blood, 2015, 126, LBA-1-LBA-1.	0.6	20
124	Hemolytic anemia and acute renal failure associated with temafloxacin-dependent antibodies. American Journal of Hematology, 1994, 46, 363-366.	2.0	19
125	Ex vivo screening for immunodominant viral epitopes by quantitative real time polymerase chain reaction (qRT-PCR). Journal of Translational Medicine, 2003, 1, 12.	1.8	19
126	Increasing hemoglobin oxygen saturation levels in sickle trait donor whole blood prevents hemoglobin S polymerization and allows effective white blood cell reduction by filtration. Transfusion, 2004, 44, 1293-1299.	0.8	19

#	Article	IF	Citations
127	LIN28A Expression Reduces Sickling of Cultured Human Erythrocytes. PLoS ONE, 2014, 9, e106924.	1.1	19
128	A Phase 1 trial of autologous monocytes stimulated ex vivo with SylatronÂ® (Peginterferon alfa-2b) and ActimmuneÂ® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer. Journal of Translational Medicine, 2018, 16, 196.	1.8	19
129	Application of droplet digital PCR for the detection of vector copy number in clinical CAR/TCR T cell products. Journal of Translational Medicine, 2020, 18, 191.	1.8	19
130	RBC autoantibodies in autoimmune lymphoproliferative syndrome. Transfusion, 2001, 41, 18-23.	0.8	18
131	Advancing Cancer Biotherapy with Proteomics. Journal of Immunotherapy, 2005, 28, 183-192.	1.2	18
132	Extracorporeal photopheresis as a therapy for autoimmune diseases. Journal of Clinical Apheresis, 2015, 30, 224-237.	0.7	18
133	Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers.. Journal of Clinical Oncology, 2020, 38, 101-101.	0.8	17
134	Pulmonary Transfusion Reactions. Seminars in Hematology, 2007, 44, 2-14.	1.8	16
135	Screening plateletpheresis donors for HLA antibodies on two highâ€throughput platforms and correlation with recipient outcome. Transfusion, 2011, 51, 504-510.	0.8	16
136	Immune mediated agranulocytosis and anemia associated with thymoma. American Journal of Hematology, 1995, 49, 336-340.	2.0	15
137	Stability of cryopreserved white blood cells (WBCs) prepared for donor WBC infusions. Transfusion, 2011, 51, 2647-2655.	0.8	15
138	Intramyocardial Bone Marrow Stem Cells in Patients Undergoing Cardiac Surgical Revascularization. Annals of Thoracic Surgery, 2020, 109, 1142-1149.	0.7	15
139	How do I structure logistic processes in preparation for outsourcing of cellular therapy manufacturing?. Transfusion, 2019, 59, 2506-2518.	0.8	14
140	Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain. Blood, 2020, 136, 50-51.	0.6	14
141	Proteomic signature of myeloproliferation and neutrophilia: analysis of serum and plasma from healthy subjects given granulocyte colony-stimulating factor. Experimental Hematology, 2005, 33, 1109-1117.	0.2	13
142	Streptococcus agalactiae sepsis after transfusion of a plateletpheresis concentrate: benefit of donor evaluation. Transfusion, 2006, 46, 649-651.	0.8	13
143	Evaluation of gene expression profiles of immature dendritic cells prepared from peripheral blood mononuclear cells. Transfusion, 2008, 48, 647-657.	0.8	13
144	Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells. Molecular Cancer Therapeutics, 2021, 20, 846-858.	1.9	13

#	Article	IF	Citations
145	Quality Controls in Cellular Immunotherapies: Rapid Assessment of Clinical Grade Dendritic Cells by Gene Expression Profiling. Molecular Therapy, 2013, 21, 476-484.	3.7	12
146	Prospective Evaluation of a Practical Guideline for Managing Positive Sterility Test Results in Cell Therapy Products. Biology of Blood and Marrow Transplantation, 2019, 25, 172-178.	2.0	12
147	Transfusion support for matched sibling allogeneic hematopoietic stem cell transplantation (1993â€“2010): factors that predict intensity and time to transfusion independence. Transfusion, 2019, 59, 303-315.	0.8	12
148	Effect of Storage on Levels of Nitric Oxide Derivatives in Blood Components. Blood, 2008, 112, 999-999.	0.6	12
149	15 kDa Granulysin versus GM-CSF for monocytes differentiation: analogies and differences at the transcriptome level. Journal of Translational Medicine, 2011, 9, 41.	1.8	11
150	Production of a cellular product consisting of monocytes stimulated with SylatronÂ® (Peginterferon) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2019, 17, 82.	1.8	11
151	A HCMV pp65 polypeptide promotes the expansion of CD4⁺ and CD8⁺ T cells across a wide range of HLA specificities. Journal of Cellular and Molecular Medicine, 2009, 13, 2131-2147.	1.6	10
152	Overcoming Challenges in Process Development of Cellular Therapies. Current Hematologic Malignancy Reports, 2019, 14, 269-277.	1.2	10
153	Antitumor vaccines, immunotherapy and the immunological constant of rejection. IDrugs: the Investigational Drugs Journal, 2009, 12, 297-301.	0.7	10
154	Interagency Genome Amplification Testing Task Force: preliminary report. Transfusion, 2003, 38, 903-904.	0.8	9
155	Factors affecting the formation of white particulate matter in red blood cell components. Transfusion, 2005, 45, 1127-1132.	0.8	9
156	Quality assessment of cellular therapies: the emerging role of molecular assays. The Korean Journal of Hematology, 2010, 45, 14.	0.7	9
157	High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses. Clinical Cancer Research, 2015, 21, 4312-4320.	3.2	9
158	Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood, 2013, 122, 68-68.	0.6	9
159	Global Transcriptional Analysis for Biomarker Discovery and Validation in Cellular Therapies. Molecular Diagnosis and Therapy, 2009, 13, 181-193.	1.6	8
160	Optimal Storage Conditions for Apheresis Research (OSCAR): a Biomedical Excellence for Safer Transfusion (BEST) Collaborative study. Transfusion, 2018, 58, 461-469.	0.8	8
161	Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome. British Journal of Haematology, 2021, 193, 951-960.	1.2	8
162	Ex Vivo Manufacture of Rapamycin-Resistant Human Th1/Tc1 Cells.. Blood, 2009, 114, 501-501.	0.6	8

#	Article	IF	Citations
163	Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity. Blood, 2021, 138, 3837-3837.	0.6	8
164	Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixaforâ€mobilized patients with sickle cell disease. British Journal of Haematology, 2022, 198, 740-744.	1.2	8
165	Neutrophilâ€Specific Antigen HNAâ€2a (NB1, CD177): Serology, Biochemistry, and Molecular Biology. Vox Sanguinis, 2002, 83, 359-361.	0.7	7
166	Allogeneic transplantation using <scp>CD</scp>34⁺ selected peripheral blood progenitor cells combined with nonâ€mobilized donor TÂcells for refractory severe aplastic anaemia. British Journal of Haematology, 2017, 176, 950-960.	1.2	7
167	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. Biology of Blood and Marrow Transplantation, 2018, 24, 175-184.	2.0	7
168	Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy. Cancer Letters, 2021, 499, 279-289.	3.2	7
169	Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR. Blood, 2018, 132, 697-697.	0.6	7
170	High efficiency closed-system gene transfer using automated spinoculation. Journal of Translational Medicine, 2021, 19, 474.	1.8	7
171	Retroviral transduction of peripheral blood leukocytes in a hollow- fiber bioreactor. Transfusion, 1997, 37, 685-690.	0.8	6
172	CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation. Supportive Care in Cancer, 2016, 24, 815-822.	1.0	6
173	Adoptive lymphocyte transfer to an HIV-infected progressor from an elite controller. JCI Insight, 2019, 4, .	2.3	6
174	Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions.. Journal of Clinical Oncology, 2018, 36, 3052-3052.	0.8	6
175	Cryopreserving and deglycerolizing sickle cell trait red blood cell components using an automated cell-processing system. Immunohematology, 2008, 24, 107-111.	0.2	6
176	Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy. Frontiers in Oncology, 2021, 11, 789078.	1.3	6
177	Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting. , 2013, 1, .		5
178	Ex vivo T-cellâ€“depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy. Cytotherapy, 2017, 19, 735-743.	0.3	5
179	Advances in T-cell Immunotherapies. Hematology/Oncology Clinics of North America, 2019, 33, 825-837.	0.9	5
180	Advances in gene therapy for hematologic disease and considerations for transfusion medicine. Seminars in Hematology, 2020, 57, 83-91.	1.8	5

#	Article	IF	Citations
181	AMD3100 and Granulocyte Colony Stimulating Factor (G-CSF) Mobilize Different CD34+ Cell Populations Based on Global Gene and Micro RNA Expression.. Blood, 2008, 112, 1385-1385.	0.6	5
182	Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).. Journal of Clinical Oncology, 2019, 37, 2639-2639.	0.8	5
183	The need for uniform and coordinated practices involving centrally manufactured cell therapies. Journal of Translational Medicine, 2022, 20, 184.	1.8	5
184	Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies. International Reviews of Immunology, 2022, 41, 638-648.	1.5	5
185	Protecting the health and safety of cell and tissue donors. ISBT Science Series, 2015, 10, 108-114.	1.1	4
186	Plasma from some cancer patients inhibits adenoviral Ad5f35 vector transduction of dendritic cells. Cytotherapy, 2018, 20, 728-739.	0.3	4
187	NADPH oxidase correction by mRNA transfection of apheresis granulocytes in chronic granulomatous disease. Blood Advances, 2020, 4, 5976-5987.	2.5	4
188	Link between Interleukin-23 and Anti-CD4 Autoantibody Production in Antiretroviral-Treated HIV-Infected Individuals. Journal of Virology, 2021, 95, .	1.5	4
189	Humanized mouse models reveal an immunologic classification of idiopathic CD4 lymphocytopenia subtypes. JCI Insight, 2019, 4, .	2.3	4
190	Abbreviated T-Cell Activation on the Automated Clinimacs Prodigy Device Enhances Bispecific CD19/22 Chimeric Antigen Receptor T-Cell Viability and Fold Expansion, Reducing Total Culture Duration. Blood, 2018, 132, 4551-4551.	0.6	4
191	Adoptive Transfer of Escalating Doses of Ex Vivo Expanded Autologous Natural Killer (NK) Cells In Patients with Advanced Malignancies Following Bortezomib Treatment to Sensitize to NK-TRAIL Cytotoxicity. Blood, 2010, 116, 4296-4296.	0.6	4
192	Association of autologous AdHER2 dendritic cell vaccination with antitumor activity and number of circulating tumor cells.. Journal of Clinical Oncology, 2017, 35, 3089-3089.	0.8	4
193	Changes in Quality-of-Life Parameters in Patients Receiving Therapeutic Interventions for Cancer-Associated Anemia: A Systematic Review. Blood, 2021, 138, 2142-2142.	0.6	4
194	Point-of-care cell therapy manufacturing; itâ€™s not for everyone. Journal of Translational Medicine, 2022, 20, 34.	1.8	4
195	Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy. Journal of Translational Medicine, 2011, 9, 107.	1.8	3
196	Longitudinal Study of Recurrent Metastatic Melanoma Cell Lines Underscores the Individuality of Cancer Biology. Journal of Investigative Dermatology, 2014, 134, 1389-1396.	0.3	3
197	Distinct Biomarker Profiles in Ex Vivo T Cell Depletion Graft Manipulation Strategies: CD34+ Selection versus CD3+/19+ Depletion in Matched Sibling Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 460-466.	2.0	3
198	Novel DNA-based T-Cell Activator Promotes Rapid T-Cell Activation and Expansion. Journal of Immunotherapy, 2020, 43, 231-235.	1.2	3

#	Article	IF	Citations
199	Therapeutic apheresis for babesiosis. Journal of Clinical Apheresis, 1998, 13, 32-36.	0.7	3
200	Upregulation of Interferon-Inducible and Damage Response Receptors in Chronic Graft-Versus-Host Disease. Blood, 2015, 126, 922-922.	0.6	3
201	Excellent Outcomes of Combined Haploidentical and Cord-Blood (Haplo-Cord) Transplantation and HLA-Matched Sibling (Matched-Sib) Donor Transplantation for High-Risk Patients with Severe Aplastic Anemia (SAA) Refractory to Immunosuppressive Therapy. Blood, 2016, 128, 4689-4689.	0.6	3
202	Effect of storage levels of nitric oxide derivatives in blood components. F1000Research, 2012, 1, 35.	0.8	3
203	LIN28A-Mediated Expression Of Fetal Hemoglobin Ameliorates Erythrocyte Sickling. Blood, 2013, 122, 313-313.	0.6	3
204	Mesenchymal stromal cell plasticity and the tumor microenvironment. Emerging Topics in Life Sciences, 2017, 1, 487-492.	1.1	2
205	Variations in novel cellular therapy products manufacturing. Cytotherapy, 2020, 22, 337-342.	0.3	2
206	Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations. Transplantation and Cellular Therapy, 2021, 27, 503.e1-503.e8.	0.6	2
207	Very Early Adoptive Transfer of Ex Vivo Generated Multi-Virus Specific T Cells Is a Safe Strategy for Prevention of Viral Infection after Allogeneic T Cell Depleted Stem Cell Transplantation. Blood, 2018, 132, 812-812.	0.6	2
208	TRALI Pathophysiology.. Blood, 2009, 114, SCI-48-SCI-48.	0.6	2
209	Excellent Engraftment and Long-Term Survival in Patients with Severe Aplastic Anemia (SAA) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Haplo-Identical CD34+ Cells Combined with a Single Umbilical Cord Blood Unit. Blood, 2015, 126, 5516-5516.	0.6	2
210	Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial. Blood, 2015, 126, 65-65.	0.6	2
211	Robust Selections of Various Hematopoietic Cell Fractions on the CliniMACS Plus Instrument. Clinical Hematology International, 2019, 1, 161-167.	0.7	2
212	Comparison of human platelet antigen (HPA)-1a typing by solid phase red cell adherence to HPA-1 allotypes determined by allelespecific restriction enzyme analysis. Immunohematology, 2000, 16, 68-73.	0.2	2
213	Global transcriptional analysis for biomarker discovery and validation in cellular therapies. Molecular Diagnosis and Therapy, 2009, 13, 181-93.	1.6	2
214	Rapid Engraftment, Immune Recovery, and Resolution of Transfusion Dependence in Treatment-Refractory Severe Aplastic Anemia Following Transplantation with Ex Vivo Expanded Umbilical Cord Blood (Omidubicel). Blood, 2020, 136, 37-38.	0.6	2
215	Identification of genomic signatures in bone marrow associated with clinical response of CD19 CAR T-cell therapy. Scientific Reports, 2022, 12, 2830.	1.6	2
216	CAR T-cells effective for post-CART relapse: A new treatment paradigm.. Journal of Clinical Oncology, 2022, 40, e19508-e19508.	0.8	2

#	Article	IF	Citations
217	Cell therapies for trauma and critical care medicine: critical issues in translation for cellular and novel therapies in trauma and critical care. Transfusion, 2019, 59, 854-857.	0.8	1
218	CAR T-Cell: Cell Processing Laboratory Considerations. , 2020, , 17-28.		1
219	Establishment of a cell processing laboratory to support hematopoietic stem cell transplantation and chimeric antigen receptor (CAR)-T cell therapy. Transfusion and Apheresis Science, 2021, 60, 103066.	0.5	1
220	Drugâ€induced hemolysis: Cefotetanâ€dependent hemolytic anemia mimicking an acute intravascular immune transfusion reaction. American Journal of Hematology, 2000, 64, 67-70.	2.0	1
221	Adoptive Transfer of Treg-Depleted Donor Th1 and Th2 Cells Safely Accelerates Alloengraftment After Low-Intensity Chemotherapy. Blood, 2010, 116, 521-521.	0.6	1
222	Fetal-to-Adult Hemoglobin Switching Is Associated with up-Regulation of Specific MicroRNA Species in Circulating Human Erythroid Cells.. Blood, 2008, 112, 1865-1865.	0.6	1
223	Ex Vivo Generation Of CD4+ T Cells To Prevent and Treat Infection From Antibiotic-Resistant Klebsiella Pneumoniae In Immunocompromised Patients. Blood, 2013, 122, 2022-2022.	0.6	1
224	Rapid Engraftment and Immune Recovery in Treatment Refractory Severe Aplastic Anemia Patients Undergoing Ex Vivo Nicotinamide-Expanded (NAM-Expanded) Unrelated Cord Blood Transplantation. Blood, 2018, 132, 5789-5789.	0.6	1
225	Developing the Next Generation of iPSC Cell-Based Immunotherapies. Blood, 2018, 132, 3707-3707.	0.6	1
226	Rapid, single-subject genotyping to predict red blood cell antigen expression. Immunohematology, 2008, 24, 154-159.	0.2	1
227	Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control. Journal of Translational Medicine, 2021, 19, 523.	1.8	1
228	Abstract CT142: GD2.Ox40.CD28.z CAR T cell trial in neuroblastoma and osteosarcoma. Cancer Research, 2022, 82, CT142-CT142.	0.4	1
229	Cell Processing: Current Status and Future Directions. Yonsei Medical Journal, 2004, 45, S1.	0.9	0
230	Dendritic cells: an immunotherapy coming of age. Immunotherapy, 2012, 4, 973-974.	1.0	0
231	Blood Research: hematology and beyond. Blood Research, 2013, 48, 1.	0.5	0
232	Potency Analysis of Cellular Therapies. , 2015, , 41-58.		0
233	Group O plasma as a media supplement for CARâ€T cells and other adoptive Tâ€cell therapies. Transfusion, 2020, 60, 1004-1014.	0.8	0
234	Transfusion support in patients with hematologic disease: Transfusions in special clinical circumstances. Seminars in Hematology, 2020, 57, 31-32.	1.8	0

#	Article	IF	Citations
235	Potency analysis of cellular therapies: the role of molecular assays. , 2021, , 49-70.		0
236	Subcelluar Distribution of Myeloid-Related Protein 8 (MRP8) and MRP14 in Human Neutrophils.. Blood, 2005, 106, 3864-3864.	0.6	0
237	Comprehensive Analysis of CD8 T Cell Immune Response Specific for Two Novel HLA-A*0201 Restriced CMV pp65 Peptides.. Blood, 2005, 106, 3928-3928.	0.6	0
238	Effect of Storage on Levels of Nitric Oxide Derivatives in Blood Components.. Blood, 2006, 108, 950-950.	0.6	0
239	Effect of Storage on Levels of Nitric Oxide Derivatives in Blood Components.. Blood, 2007, 110, 2884-2884.	0.6	0
240	The Emerging Role of RH Genotyping in Chronically Transfused Sickle Cell Disease Patients. Blood, 2008, 112, 3035-3035.	0.6	0
241	Global Gene Expression Signatures in CD34+ Hematopoietic Cells Following Exposure to 16,16-Dimethylprostaglandin E2.. Blood, 2009, 114, 2523-2523.	0.6	0
242	Comparative Global Transcriptome Analysis of Bone Marrow Stromal Cells (BMSC), Human Embryonic Stem (hES) Cells and CD34+ Cells.. Blood, 2009, 114, 36-36.	0.6	0
243	Clinical Applications of Activated Immune Cells. , 2011, , 93-102.		0
244	Tracking Senescence In Human Bone Marrow Stromal Cell (BMSC) Cultures.. Blood, 2010, 116, 1179-1179.	0.6	0
245	Peripheral Blood Stem Cell (PBSC) Donors Experience Higher Levels of Pain and Toxicities Early On, While Bone Marrow (BM) Donors Experience Slower Recovery and More Late Pain: A Prospective Study of the National Marrow Donor Program (NMDP).. Blood, 2010, 116, 1107-1107.	0.6	0
246	Selective Depletion of T Cell Alloresponses Using a Photodepletion Strategy Preferentially Targets CD4+ T Cells.. Blood, 2010, 116, 1467-1467.	0.6	0
247	Microarray Analysis of CD34+CXCR4+ and CD34+CXCR4- Cells Reveals Two Distinct Hematopoietic Stem/Progenitor Populations. Blood, 2010, 116, 4798-4798.	0.6	0
248	Selectively T Cell Depleted Allografts From HLA-Matched Sibling Donors Followed by Low-Dose Post Transplant Immunosuppression to Limit Disease Relapse In Patients with Hematological Malignancies. Blood, 2010, 116, 4705-4705.	0.6	0
249	4-Log Ex-Vivo T-Lymphocyte Depleted Myeloablative HLA-Matched Sibling Transplants; a Platform for Adoptive Immunotherapy. Blood, 2010, 116, 2091-2091.	0.6	0
250	Evaluation of Human and Rhesus CD34+CXCR4+ and CD34+CXCR4- Subpopulations. Blood, 2011, 118, 1007-1007.	0.6	0
251	The Microarray Signature of Rhesus Macaque CD34+CD123 (IL-3 Receptor)+ Hematopoietic Stem/Progenitor Cells Isolated Following Mobilization with Plerixafor Alone or in Combination with Granulocyte Colony-Stimulating Factor (G-CSF). Blood, 2011, 118, 1301-1301.	0.6	0
252	Phase 1 Trial Of Bone Marrow Stromal Cells (Bone Marrow-derived MSCS) To Treat Tissue Damage In Allogeneic Stem Cell Transplant Recipients: Biological Markers Correlate With Clinical Responses and Survival. Blood, 2013, 122, 3282-3282.	0.6	0

#	Article	IF	Citations
253	CD34+CXCR4(CD184)+ Cells Differentiate Into Myeloid Dendritic Cell Progenitors. Blood, 2013, 122, 4835-4835.	0.6	0
254	Reduced Non Relapse Mortality (NRM) and Survivable Acute Graft Versus Host Disease (GVHD) in the Current Era of Myeloablative Ex Vivo T-Cell Depleted (TCD) Transplantation. Blood, 2016, 128, 4596-4596.	0.6	0
255	Safety and Feasibility of Ultra-Low Dose IL-2 As Graft Versus Host Disease Prophylaxis in Haplo-Identical Stem Cell Transplantation- a Proof of Concept Pilot Study. Blood, 2016, 128, 386-386.	0.6	0
256	Pain, Symptoms, AEs, and Recovery after Second Unrelated Donor Collection of Marrow/Peripheral Blood Stem Cells Are Similar to Those of the First Donation. Blood, 2016, 128, 2177-2177.	0.6	0
257	Early Adoptive Transfer of Ex Vivo Generated Multi-Virus Specific T Cells Is a Safe Strategy to Prevent Viral Reactivation in Recipients of Allogeneic T Cell Depleted Stem Cell Transplant. Blood, 2016, 128, 979-979.	0.6	0
258	Distinct Biomarker Profiles in Ex-Vivo T Cell Depletion Graft Manipulation Strategies: CD34+ Selection Vs CD3/19 Depletion in Matched Sibling Allogeneic Peripheral Blood Stem Cell Transplantation. Blood, 2016, 128, 657-657.	0.6	0
259	Robust Cell Selections and Depletions across Various Hematopoietic Cell Fractions on the Clinimacs Plus Instrument. Blood, 2018, 132, 3818-3818.	0.6	0
260	A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy with Ex Vivo Generated Polyomavirus-Specific T-Cells. Blood, 2018, 132, 4535-4535.	0.6	0
261	Production of autologous monocytes stimulated ex vivo with peg-interferon alfa 2b and interferon gamma 1b for intraperitoneal administration in phase I clinical trial.. Journal of Clinical Oncology, 2019, 37, 5-5.	0.8	0
262	Optimization of Autologous Hematopoietic Progenitor Stem Cell Apheresis Collection from Plerixafor-Mobilized Patients with Sickle Cell Disease. Blood, 2021, 138, 1770-1770.	0.6	0
263	Longitudinal Transcriptional Analysis of Peripheral Blood Leukocytes in COVID Convalescent Donors. Blood, 2021, 138, 1767-1767.	0.6	0
264	Cell Density of NK Cells during Ex Vivo Expansion Impacts NK Cell Surface TRAIL Expression. Blood, 2020, 136, 5-6.	0.6	0